Neuroleptic Malignant Syndrome
GPTKB entity
Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medical condition
syndrome |
| gptkbp:affects |
central nervous system
autonomic nervous system muscular system |
| gptkbp:alsoKnownAs |
gptkb:NMS
|
| gptkbp:causedBy |
antipsychotic drugs
dopamine antagonists |
| gptkbp:characterizedBy |
autonomic dysfunction
hyperthermia altered mental status muscle rigidity |
| gptkbp:complication |
gptkb:arrhythmia
renal failure rhabdomyolysis |
| gptkbp:diagnosedBy |
clinical assessment
laboratory tests |
| gptkbp:differentialDiagnosis |
gptkb:serotonin_syndrome
malignant hyperthermia catatonia |
| gptkbp:firstDescribed |
1960
|
| gptkbp:frequency |
rare
|
| https://www.w3.org/2000/01/rdf-schema#label |
Neuroleptic Malignant Syndrome
|
| gptkbp:ICD-10_code |
G21.0
|
| gptkbp:MeSH_ID |
gptkb:D009474
|
| gptkbp:mortalityRate |
10-20%
|
| gptkbp:namedFor |
gptkb:Delay_and_Deniker
|
| gptkbp:notableCase |
gptkb:Haloperidol-induced_NMS
gptkb:Risperidone-induced_NMS |
| gptkbp:population |
patients on antipsychotics
|
| gptkbp:prevention |
careful antipsychotic dosing
monitoring for early symptoms |
| gptkbp:prognosis |
potentially fatal
|
| gptkbp:riskFactor |
dehydration
agitation high-potency antipsychotics rapid dose escalation |
| gptkbp:symptom |
fever
delirium elevated creatine kinase sweating tachycardia labile blood pressure |
| gptkbp:treatment |
gptkb:amantadine
gptkb:dantrolene supportive care bromocriptine discontinuation of antipsychotic |
| gptkbp:bfsParent |
gptkb:NMS
|
| gptkbp:bfsLayer |
6
|